Masayuki Tomita

Suggest Changes
Learn More
Evidence on sequential trial with atypical antipsychotics has been scarce. We conducted an algorithm-based antipsychotic pharmacotherapy. In this open-label study, patients with schizophrenia(More)
BACKGROUND In order to change the immunological environment of T-helper2 (Th2) predominance, namely humoural immunity, in renal cell carcinoma, we tried to examine the efficacy of combined treatment(More)